Status:
COMPLETED
The Effect of RAAS Blockers on ACE2 Levels
Lead Sponsor:
Ain Shams University
Conditions:
Renin-Angiotensin System
Eligibility:
All Genders
43-67 years
Brief Summary
Blockage of renin-angiotensin-aldosterone system (RAAS) by angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARBs) is considered the first-choice of drugs for treatmen...
Detailed Description
Blockage of renin-angiotensin-aldosterone system (RAAS) by angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARBs) is considered the first-choice of drugs for treatmen...
Eligibility Criteria
Inclusion
- Patients age\> 18 years
- Taking ACE II inhibitors or angiotensin II blockers (according to maximum tolerated dose specified by guidelines)
- History of essential hypertension or heart failure
Exclusion
- patients who suffer from secondary hypertension, including idiopathic hyperaldosteronism, renal artery stenosis
- Patient reported history of severe liver disease
- a history or suspicion of alcohol or drug abuse; and mental illness
- Pregnant and breast feeding
Key Trial Info
Start Date :
June 15 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 20 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05418361
Start Date
June 15 2021
End Date
February 20 2022
Last Update
May 15 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ainshams University
Cairo, Select A State Or Province, Egypt, 02